Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)

被引：0

作者：

Ioka, T. ^{[1
]}

Nakamori, S. ^{[2
]}

Sugimori, K. ^{[3
]}

Kanai, M. ^{[4
]}

Ikeda, M. ^{[5
]}

Ozaka, M. ^{[6
]}

Furukawa, M. ^{[7
]}

Okusaka, T. ^{[8
]}

Kawabe, K. ^{[9
]}

Furuse, J. ^{[10
]}

Komatsu, Y. ^{[11
]}

Sato, A. ^{[12
]}

Shimizu, S. ^{[13
]}

Chugh, P. ^{[14
]}

Tang, R. ^{[15
]}

Ueno, M. ^{[16
]}

机构：

[1] Osaka Int Canc Inst, Dept Canc Survey & Gastrointestinal Oncol, Osaka, Japan

[2] NHO Osaka Natl Hosp, Dept Surg, Osaka, Japan

[3] Yokohama City Univ, Med Ctr, Gastroenterol Ctr, Yokohama, Kanagawa, Japan

[4] Kyoto Univ Hosp, Dept Med Oncol, Kyoto, Japan

[5] Hosp East, Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Kashiwa, Chiba, Japan

[6] Canc Inst Hosp JFCR, Dept Gastroenterol, Tokyo, Japan

[7] NHO Kyushu Canc Ctr, Dept Gastroenterol Hepatol Pancreatol, Fukuoka, Fukuoka, Japan

[8] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan

[9] Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Fukuoka, Fukuoka, Japan

[10] Kyorin Univ, Fac Med, Dept Med Oncol, Mitaka, Tokyo, Japan

[11] Hokkaido Univ Hosp, Canc Ctr, Sapporo, Hokkaido, Japan

[12] Hirosaki Univ Hosp, Dept Oncol, Hirosaki, Aomori, Japan

[13] Saitama Canc Ctr, Dept Gastroenterol, Saitama, Japan

[14] Servier Pharmaceut, Clin Sci, Boston, MA USA

[15] Servier Pharmaceut, Biostat & Programming, Boston, MA USA

[16] Kanagawa Canc Ctr, Hepatobiliary & Pancreat Med Oncol Div, Dept Gastroenterol, Yokohama, Kanagawa, Japan

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

132P

引用

页数：2

共 50 条

[21] Subgroup analysis by prior lines of metastatic therapy (mtx) in NAPOLI-1: A global, randomized phase 3 study of liposomal irinotecan (nal-IRI) ± 5-fluorouracil and leucovorin (5-FU/LV), vs. 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) who have progressed following gemcitabine-based therapy.
Bodoky
Dean, Andrew Peter
Yanshen, Shan
Jameson, Gayle S.
Lee, Kyung-Hun
Blanc, Jean-Frederic
Chiu, Chang-Fang
Schwartsmann, Gilberto
Braiteh, Fadi S.
Cunningham, David
Chen, Li-Tzong
Von Hoff, Daniel D.
Mamlouk, Khalid Kevin
Bhargava, Parul
de Jong, Floris A.
Hubner, Richard
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[22] Nomogram for predicting overall survival (OS) in patients (pts) treated with liposomal irinotecan (nal-IRI) ± 5-fluorouracil/leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy in NAPOLI-1
Wang-Gillam, Andrea
Hubner, Richard
Mirakhur, Beloo
de Jong, Floris A.
Belanger, Bruce
Chen, Li-Tzong
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[23] Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1
Chen, L-T.
Macarulla, T. M.
Blanc, J.
Mirakhur, B.
de Jong, F. A.
Belanger, B.
Bekaii-Saab, T.
Siveke, J.
ANNALS OF ONCOLOGY, 2018, 29 : 250 - U388
[24] Liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU) and leucovorin (LV) or gemcitabine plus cisplatin in advanced cholangiocarcinoma: The AIO-NIFE-trial, an open label, randomized, multicenter phase II trial.
Ettrich, Thomas Jens
Berger, Andreas Wolfgang
Seufferlein, Thomas
Perkhofer, Lukas
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[25] Multicenter retrospective analysis for efficacy and safety of liposomal irinotecan (nal-IRI) plus 5-FU/leucovorin (5-FU/LV) after progression on gemcitabine-based therapy in Korean patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A study by Korean Cancer Study Group (KCSG).
Im, Hyeon-Su
Kim, Kyu-Pyo
Oh, Do-Youn
Lee, Kyung-Hun
Chon, Hong Jae
Kim, Joo Hoon
Kang, Myoung Joo
Kim, Il-Hwan
Lee, Guk Jin
Oh, Sung Yong
Choi, Younak
Choi, Hye Jin
Kim, Seung Tae
Park, Joon Oh
Ryoo, Baek-Yeol
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[26] Liposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: Further subgroup analyses of the pivotal NAPOLI-1 study
Chen, L-T.
Macarulla Mercade, T.
Lee, K-H.
Lakatos, G.
Wang-Gillam, A.
Mirakhur, B.
de Jong, F.
ANNALS OF ONCOLOGY, 2018, 29
[27] A randomised phase II study comparing irinotecan (IRI) plus leucovorin (LV) and 5-fluorouracil (5FU) versus IRI-LV-5FU followed be oxaliplatin (OXA) plus LV-5FU in patients with previously untreated metastatic colorectal cancer (CRC).
Kalofonos, H. P.
Papakostas, P.
Aravantinos, G.
Papadimitriou, C.
Pentheroudakis, G.
Varthalitis, I.
Tsavdaridis, D.
Syrigos, K.
Kosmidis, P.
Fountzilas, G.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 166S - 166S
[28] The prognostic value of baseline neutrophilto-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398)+5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV.
Wang-Gillam, Andrea
Chen, Li-Tzong
Li, Chung-Pin
Bodoky, Gyorgy
Dean, Andrew
Lee, Kyung-Hun
Cunningham, David
Hubner, Richard
Braiteh, Fadi S.
Pipas, J. Marc
Belanger, Bruce
de Jong, Floris A.
Mody, Purvi D.
Von Hoff, Daniel D.
Siveke, Jens T.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[29] The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV)
Chen, L-T.
Macarulla, T. M.
Belanger, B.
Mirakhur, B.
de Jong, F. A.
Siveke, J.
ANNALS OF ONCOLOGY, 2018, 29
[30] NIFE-trial: Liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU) and leucovorin (LV) or gemcitabine plus cisplatin in advanced biliary-tract cancer: An open label, randomized, multicenter phase II trial of the AIO
Ettrich, T. J.
Perkhofer, L.
Berger, A. W.
Seufferlein, T.
ANNALS OF ONCOLOGY, 2017, 28

← 1 2 3 4 5 →